JangYJPark KH SeokHJManagement of Kikuchi's disease using glucocorticoidJ. Laryngol. Otol.2000114709–1110.1258/0022215001906561
2.
RezaiKKuchipudiSChundiVKikuchi–Fujimoto disease: hydroxychloroquine as a treatmentClin. Infect. Dis200439e124–e12610.1086/426144
3.
LawrenceRCHelmickCGArnettFCEstimates of the prevalence of arthritis and selected musculoskeletal disorders in the United StatesArthritis Rheum.199841778–79910.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V
4.
JimenezSCerveraRFontJThe epidemiology of systemic lupus erythematosusClin. Rev. Allergy Immunol.2003253–1210.1385/CRIAI:25:1:3
5.
El-RamahiKMKarrarAAliMAKikuchi disease and its association with systemic lupus erythematosusLupus19943409–1110.1177/096120339400300508
6.
GoldblattFAndrewsJRussellAIsenbergDAssociation of Kikuchi–Fujimoto's disease with SLERheumatology200847554–555
7.
EisnerMDAmoryJMullaneyBNecrotizing lymphadenitis associated with systemic lupus erythematosusSemin. Arthritis Rheum.1996261–610.1016/S0049-0172(96)80028-X
8.
OhshimaKKarubeKHamasakiMApoptosis- and cell cycle-associated gene expression profiling of histiocytic necrotising lymphadenitisEur. J. Haematol.200472322–910.1111/j.1600-0609.2004.00226.x
9.
KatoKOhshimaKAnzaiKElevated serum-soluble Fas ligand in histiocytic necrotizing lymphadenitisInt. J. Hematol.20017384–610.1007/BF02981907
10.
KozyrevSVLewénSReddyPMStructural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosusArthritis Rheum2007561234–4110.1002/art.22497
11.
NiewoldTBKellyJAFleschMHAssociation of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patientsArthritis Rheum.2008582481–710.1002/art.23613
12.
GrahamRRKyogokuCSigurdssonSThree functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupusProc Natl Acad Sci U S A.20071046758–6763
13.
KirouKAMavraganiCPCrowMKActivation of typeI interferon in systemic lupus erythematosusExpert Rev. Clin. Immunol.20073579–588
14.
BarratFJMeekerTGregorioJNucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosusJ. Exp. Med.20052021131–1139
15.
CellaMJarrossayDFacchettiFPlasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferonNat. Med.19995919–92310.1038/11360
16.
QuCMoranTMRandolphGJAutocrine type I IFN and contact with endothelium promote the presentation of influenza A virus by monocyte-derived APCJ. Immunol20031701010–1018
17.
TsangWYChanJKNgCSKikuchi's lymphadenitis. A morphologic analysis of 75 cases with special reference to unusual featuresAm. J. Surg. Pathol.199418219–23110.1097/00000478-199403000-00001
18.
HeremansHBilliauAColombattiAInterferon treatment of NZB mice: accelerated progression of autoimmune diseaseInfect. Immun.197821925–930
19.
BraunDGeraldesPDemengeotJType I interferon controls the onset and severity of autoimmune manifestations in lpr miceJ. Autoimmun.20032015–2510.1016/S0896-8411(02)00109-9
20.
AdamCThouaYRoncoPThe effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 miceClin. Exp. Immunol.198040373–382
21.
MathianAWeinbergAGallegosMIFN-{alpha} induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but Not in BALB/c MiceJ. Immunol.20051742499–2506
HronJDPengSLType I IFN protects against murine lupusJ. Immunol.20041732134–2142
24.
BaechlerECBatliwallaFMKarypisGInterferon-inducible gene expression signature in peripheral blood cells of patients with severe lupusProc Natl Acad Sci USA20031002610–261510.1073/pnas.0337679100
25.
CrowMKKirouKAWohlgemuthJMicroarray analysis of interferon-regulated genes in SLEAutoimmunity200336481–49010.1080/08916930310001625952
26.
BennettLPaluckaAKArceEInterferon and granulopoiesis signatures in systemic lupus erythematosus bloodJ. Exp. Med.2003197711–72310.1084/jem.20021553
27.
KirouKALeeCGeorgeSCoordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosusArthritis Rheum.2004503958–396710.1002/art.20798
28.
FarkasLBeiskeKLund-JohansenFPlasmacytoid dendritic cells (natural interferon- {{alpha}}/{beta}-producing cells) accumulate in cutaneous lupus erythematosus lesionsAm. J. Pathol.2001159237–243
29.
BlombergSElorantaMLCederbladBPresence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosusLupus200110484–49010.1191/096120301678416042
30.
NakanoHYanagitaMGunnMDCD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cellsJ. Exp. Med.20011941171–117810.1084/jem.194.8.1171
31.
YoneyamaHMatsunoKTodaEPlasmacytoid DCs help lymph node DCs to induce anti-HSV CTLsJ. Exp. Med.2005202425–43510.1084/jem.20041961
32.
ShiowLRRosenDBBrdickovaNCD69 acts downstream of interferon-[alpha]/[beta] to inhibit S1P1 and lymphocyte egress from lymphoid organsNature2006440540–544
